These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 16777690)

  • 1. A Phase II NCCTG study of irinotecan and docetaxel in previously treated patients with non-small cell lung cancer.
    Molina JR; Nikcevich D; Hillman S; Geyer S; Drevyanko T; Jett J; Verdirame J; Tazelaar H; Rowland K; Wos E; Kutteh L; Nair S; Fitch T; Flynn P; Stella P; Adjei AA
    Cancer Invest; 2006; 24(4):382-9. PubMed ID: 16777690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triple combination chemotherapy with cisplatin, docetaxel, and irinotecan for advanced non-small cell lung cancer: a phase I/II trial.
    Kiura K; Takigawa N; Segawa Y; Tabata M; Shibayama T; Gemba K; Bessho A; Fujimoto N; Takata I; Hotta K; Fujiwara K; Tokuda Y; Kuyama S; Shinkai T; Ueoka H; Tanimoto M;
    J Thorac Oncol; 2007 Jan; 2(1):44-50. PubMed ID: 17410009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of biweekly administration of docetaxel and irinotecan in patients with refractory or relapsed advanced non-small cell lung cancer.
    Hirose T; Shirai T; Ishida H; Ando K; Sugiyama T; Kusumoto S; Hosaka T; Nakashima M; Ohmori T; Adachi M
    Cancer Chemother Pharmacol; 2007 Jul; 60(2):267-74. PubMed ID: 17273827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of cisplatin combined to irinotecan administered alternatingly with docetaxel in advanced non-small cell lung cancer.
    Charoentum C; Thongprasert S; Chewasakulyong B; Euathrongchit J; Sorraritchingchai S; Munprakan S
    J Med Assoc Thai; 2007 Nov; 90(11):2506-12. PubMed ID: 18181342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequential chemotherapy with combination irinotecan and cisplatin followed by docetaxel for treatment-naïve patients with advanced non-small cell lung cancer.
    Mok TS; Ho S; Chan G; Ho WM; Wong H; Chan AT; Yeo W; Yim AP; Chak K; Lee Y; Lam KC
    J Thorac Oncol; 2007 Sep; 2(9):838-44. PubMed ID: 17805062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biweekly docetaxel-irinotecan with filgrastim support in pretreated breast and non-small-cell lung cancer patients. A phase I study.
    Frasci G; Comella P; Thomas R; Di Bonito M; Lapenta L; Capasso I; Botti G; Vallone P; De Rosa V; D'Aiuto G; Comella G
    Cancer Chemother Pharmacol; 2004 Jan; 53(1):25-32. PubMed ID: 14513281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Irinotecan and vinorelbine in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. A phase II study of the Hellenic Cooperative Oncology Group.
    Pectasides D; Fountzilas G; Rigopoulos A; Bountouroglou NG; Koutras A; Glotsos J; Onyenadum A; Makatsoris T; Kalofonos HP
    Anticancer Res; 2002; 22(6B):3501-6. PubMed ID: 12552946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of irinotecan and docetaxel in patients with previously treated non-small cell lung cancer: an Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 007).
    Grossi F; Fasola G; Rossetto C; Spizzo R; Meduri S; Sibau A; Vigevani E; Tumolo S; Adami G; Sacco C; Recchia L; Rizzato S; Ceschia T; Belvedere O
    Lung Cancer; 2006 Apr; 52(1):89-92. PubMed ID: 16483688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Docetaxel and irinotecan, alone and in combination, in the treatment of non-small cell lung cancer.
    Adjei AA; Argiris A; Murren JR
    Semin Oncol; 1999 Oct; 26(5 Suppl 16):32-40; discussion 41-2. PubMed ID: 10585007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase II study of weekly irinotecan and capecitabine in patients with previously treated non-small cell lung cancer.
    Han JY; Lee DH; Kim HY; Kim EA; Lee JJ; Ju SY; Shin EH; Lee JS
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5909-14. PubMed ID: 14676114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Front-line treatment of advanced non-small cell lung cancer with irinotecan and docetaxel: a multicentre phase II study.
    Ziotopoulos P; Androulakis N; Mylonaki E; Chandrinos V; Zachariadis E; Boukovinas I; Agelidou A; Kentepozidis N; Ignatiadis M; Vossos A; Georgoulias V;
    Lung Cancer; 2005 Oct; 50(1):115-22. PubMed ID: 15993981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Docetaxel consolidation therapy following cisplatin, vinorelbine, and concurrent thoracic radiotherapy in patients with unresectable stage III non-small cell lung cancer.
    Sekine I; Nokihara H; Sumi M; Saijo N; Nishiwaki Y; Ishikura S; Mori K; Tsukiyama I; Tamura T
    J Thorac Oncol; 2006 Oct; 1(8):810-5. PubMed ID: 17409964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb-IV non-small-cell lung cancer who failed first-line treatment.
    Wachters FM; Groen HJ; Biesma B; Schramel FM; Postmus PE; Stigt JA; Smit EF
    Br J Cancer; 2005 Jan; 92(1):15-20. PubMed ID: 15597104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of docetaxel and docetaxel-irinotecan combination as second-line chemotherapy in advanced non-small-cell lung cancer: a randomized phase II trial.
    Pectasides D; Pectasides M; Farmakis D; Kostopoulou V; Nikolaou M; Gaglia A; Koumpou M; Mylonakis N; Xiros N; Economopoulos T; Raptis SA
    Ann Oncol; 2005 Feb; 16(2):294-9. PubMed ID: 15668287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II study of weekly docetaxel-cisplatin as first-line treatment for advanced non-small cell lung cancer.
    Binder D; Hackenthal M; Graseck L; Schweisfurth H; Schäper C; Krüll M; Temmesfeld-Wollbrück B; Suttorp N; Beinert T; Hellriegel KP
    J Thorac Oncol; 2009 Sep; 4(9):1144-7. PubMed ID: 19609222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triplet chemotherapy with cisplatin, docetaxel, and irinotecan for patients with recurrent or refractory non-small cell lung cancer.
    Fujimoto N; Kiura K; Takigawa N; Fujiwara Y; Toyooka S; Umemura S; Tabata M; Ueoka H; Tanimoto M
    Acta Med Okayama; 2010 Feb; 64(1):33-7. PubMed ID: 20200582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Docetaxel-carboplatin chemotherapy combined with cetuximab in patients with locally advanced or metastatic non small-cell lung cancer (NSCLC)--results of the nonrandomised phase II study TaxErb.
    Fischer JR; Griesinger F; Fink T; Salm T; Marseille A; Wolf M
    Lung Cancer; 2012 Mar; 75(3):348-52. PubMed ID: 21908069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of carboplatin combined with weekly docetaxel in patients with advanced non-small cell lung cancer.
    Jiang L; Wang DY; Zhu ZH; Tang LF; Hou XH; Zhao HD; Xie Z; Wang DF
    Cancer Chemother Pharmacol; 2010 Aug; 66(3):449-53. PubMed ID: 19937029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic or unresectable localized non-small-cell lung cancer.
    Kim YH; Kim JS; Choi YH; In KH; Park HS; Hong DS; Jeong TJ; Lee YY; Nam E; Lee SN; Lee KS; Kim HK
    Int J Clin Oncol; 2002 Apr; 7(2):114-9. PubMed ID: 12018108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: preliminary evidence of clinical activity.
    Adjei AA; Klein CE; Kastrissios H; Goldberg RM; Alberts SR; Pitot HC; Sloan JA; Reid JM; Hanson LJ; Atherton P; Rubin J; Erlichman C
    J Clin Oncol; 2000 Mar; 18(5):1116-23. PubMed ID: 10694565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.